DENOSUMAB AND BISPHOSPHONATES PERSISTENCE, COMPLIANCE AND SWITCH IN PATIENTS WITH SOLID TUMORS (ST) AND BONE METASTASES (BM)
Author(s)
Diel I1, Ansorge S2, Hohmann D3, Giannopoulou C4, Intorcia M4
1Praxisklinik am Rosengarten, Mannheim, Germany, 2Gesundheitsforen Leipzig GmbH, Munich, Germany, 3Amgen GmbH, Munich, Germany, 4Amgen GmbH, Zug, Switzerland
OBJECTIVES: This observational study aimed to provide real-world data on denosumab and bisphosphonate use in patients with ST and BM in Germany. METHODS: This is a retrospective analysis of a German sick-fund claims database (including ~4 million patients). The study population consisted of ST patients aged ≥18 years, newly diagnosed with BM with no prior hypercalcemia, initiating denosumab or bisphosphonates. Persistence was defined as continuous prescriptions with <90-days gaps. Compliance was defined as ≥12 prescriptions in a 12-month period. Switch was defined as change in drug within 90 days. Dying patients were censored on the day of death. RESULTS: CONCLUSIONS: Denosumab had higher persistence and compliance with lower switch rates.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PCN285
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Hospital and Clinical Practices, Prescribing Behavior, Treatment Patterns and Guidelines
Disease
Musculoskeletal Disorders, Oncology